Acetaldehyde inhibits serum aminopeptidases

Effect of acetaldehyde upon cathepsin G and chymase. NRAS implications

Hypertension is commonly observed in alcoholics. Both the renin-angiotensin system (RAS) and the non-renin-angiotensin system (NRAS) have been implicated in the dynamics of blood pressure maintenance. In bilaterally nephrectomized rats, acetaldehyde has been reported to enhance the generation of the rate-limiting angiotensin I (ANG I) in the plasma, and in humans it inhibits the activity of several angiotensinases (A, B, and M) in the serum, thereby promoting a hypertensive set of reactions. We report here the results of a study on the effect of acetaldehyde upon cathepsin G and mast cell chymase. Acetaldehyde enhanced cathepsin G activity at all of the concentrations tested between 11.2 and 223.5 mM in a statistically significant manner. Since cathepsin G is one of several enzymes transforming ANG I into ANG II and is also capable of cleaving ANG II directly from angiotensinogen, we suggest that alcoholism, which will generate exogenous acetaldehyde from ingested alcohol, may be a contributory factor for an elevated cathepsin G activity and, consequently, hypertension via the NRAS. Chymase activity also is elevated in the presence of 440 mM acetaldehyde and diminished in the presence of 27 mM acetaldehyde. Since both enzymes also degrade ANG II, the degradative effects of each enzyme on ANG II may neutralize one another.

Ethanol inhibitory effect on rat kidney brush border aminopeptidases

BACKGROUND/AIM

Confusing data have been reported about the effect of ethanol or its metabolic products on blood pressure. The pressor agent, angiotensin II (Ang II), is found to be susceptible to degradation by different enzymes known as angiotensinases. We have studied the effects of ethanol and L-NAME, an inhibitor of nitric oxide synthase, consumption on rat serum and kidney ectoenzymes: aminopeptidase N (APN) and aminopeptidase A (APA).

METHODS

Enzymatic activity of both enzymes was determined spectrophotometrically in serum and 10% homogenates of the rat kidney cortex using appropriate chromogenic substrates.

RESULTS

After 2 weeks of treatment with ethanol and L-NAME, blood urea and creatinine levels were significantly increased. The activities of APN (EC 3.4.11.2) and APA (EC 3.4.11.7) were reduced in serum as well as in kidney tissue during this period. L-NAME significantly attenuated activities of both enyzmes. Ethanol and L-NAME given simultaneously did not have an additional effect on the activity of investigated enzymes.

CONCLUSION

Hypertension caused by chronic ethanol treatment as well as L-NAME administration could be associated with the reduction of APN and APA activity. Possible ethanol- and L-NAME-mediated inhibition of angiotensins degrading aminopeptidases could potentiate their effects on blood pressure.

Ethanol modulates neuropeptide-degrading aminopeptidases at synapse level in calcium-dependent conditions

AIMS

To investigate the role of aminopeptidases in the pathways to peptides neurotransmission/neuromodulation ending in the actions of ethanol (EtOH) on the brain.

METHODS

The effects of EtOH on alanyl-, arginyl-, cystyl-, leucyl- and tyrosyl-aminopeptidase activities were studied under basal/resting and K+-stimulated conditions at the synapse level, using mouse frontal cortex synaptosomes and their incubation supernatant in a Ca2+-containing or Ca2+-free medium.

RESULTS

Under basal conditions, synaptosome aminopeptidase activities showed an inhibitory or biphasic response depending on the concentration of EtOH used and the aminopeptidase assayed, whereas supernatant activities showed a more complex response. Under K+-stimulated conditions, EtOH inhibited all synaptosome aminopeptidases assayed in presence of Ca2+. However, in absence of Ca2+, different responses were obtained depending on the concentration of EtOH used. In the supernatant, the highest concentration of EtOH inhibited the K+-stimulated increase on aminopeptidase activities, although the lowest concentration enhanced the release in presence of Ca2+. In absence of it, EtOH blocked the K+-stimulated decrease or increased the activity depending on the concentration of EtOH used.

CONCLUSIONS

The changes on aminopeptidase activities induced by EtOH may reflect the functional status of their corresponding endogenous substrates. EtOH may influence opioid peptides, oxytocin, vasopressin and the brain renin-angiotensin system through their degrading enzymes.

Plasma aminopeptidase activities in rats after left and right intrastriatal administration of 6-hydroxydopamine

Asymmetries in the neuroendocrine system extend from central structures to paired endocrine glands and their innervation. In addition to the well-known asymmetry in the function of brain dopamine, there are also asymmetries in the peripheral response to experimental hemi-parkinsonism, performed by means of lesions of the nigrostriatal system with 6-hydroxydopamine (6-OHDA) injections into the left or right hemisphere. Therefore, it is speculated that the neuroendocrine system would also be asymmetrically affected in experimental hemi-parkinsonism. Aminopeptidases (AP) play a major role in the control of peptide concentration at both central and peripheral levels in tissues and blood, thus reflecting the functional status of their endogenous substrates. Therefore, to evaluate the peripheral response of hemi-parkinsonism, we have performed a comprehensive study of plasma AP activities after lesions of the nigrostriatal system with 6-OHDA administered into either left or right striatum of adult male rats. Saline was injected into control groups. AlaAP, CysAP, AspAP and GluAP activities were determined in plasma, using specific arylamides as substrates. Plasma AlaAP activity increased 3-fold (p < 0.001) whereas AspAP activity decreased by 30% (p < 0.05) after lesion of the right hemisphere. In contrast, CysAP and GluAP activities increased significantly after lesion of the left hemisphere by 200 and 50%, respectively (p < 0.05). The main discovery of the present results demonstrates that experimental hemi-parkinsonism affects differentially the plasma AP activities depending on the hemisphere in which the lesion is performed. This suggests that the circulating hormones, susceptible to be hydrolyzed by these enzymatic activities, are also modified.

Effect of ethanol and acetaldehyde on intracellular protease activities in human liver, brain and muscle tissues in vitro

The effect of ethanol and acetaldehyde on the activity of a range of intracellular cytoplasmic and lysosomal proteolytic enzymes has been determined in human brain, liver and skeletal muscle tissues in vitro. There was a substantial degree of inhibition for most protease types in all tissues if sufficiently high concentrations of ethanol (10%, v/v; 1.7 mol/L) or acetaldehyde (1%, v/v; 0.17 mol/L) were used in the assay media. However, it was concluded that direct inhibition of proteases in vivo by ethanol or acetaldehyde is improbable, at the concentrations of these agents likely to pertain in vivo, and that any effect of these agents on intracellular protein catabolism must occur via a more subtle biochemical mechanism.

A perspective on acetaldehyde concentrations and toxicity in man and animals

Acetaldehyde (AcH) at a concentration of 593 mM lowers the natural fluorescence of commercial human serum by 12%. It also lowers the fluorescence of a beta-naphthylamine standard curve (recovery) in serum by 17%. These results contrast with earlier reports showing that 447 mM AcH had no effect upon fluorescence of serum or a beta-naphthylamine standard curve in serum. Because 447 mM AcH and 593 mM AcH represent 2.5% and 3.3% AcH, it is apparent that there is a narrow window between which AcH may affect fluorescence by adduct formation with blood components and exogenous fluorophores. Nonetheless, serum has the capacity to bind > 2.5% (> 447 mM) AcH without alteration in fluorescence, suggesting that serum has a great carrying capacity for AcH, undoubtedly in the form of adducts to nucleophiles. These results are discussed in the light of toxicity of AcH and ethanol, the probable significance of the approximately 30 microM free AcH that is reported in chronic alcoholics and the planning of in vitro and in vivo studies with AcH.

A hypothesis linking hypoglycemia, hyperuricemia, lactic acidemia, and reduced gluconeogenesis in alcoholics to inactivation of glucose-6-phosphatase activity by acetaldehyde

Preliminary data have been obtained indicating that glucose-6-phosphatase is inactivated upon preincubation with 447 and 224 mM acetaldehyde for 30 min at room temperature, resulting in a loss of 67% and 33% of the original activity, respectively. The reaction with acetaldehyde is rapid because 44% of the enzymic activity is lost in 5 min. Comparable quantities of ethanol inhibit the enzyme to the extent of 11%, indicating a very slight, statistically insignificant organic solvent effect. Because chronic alcoholics present a clinical picture of hypoglycemia, hyperuricemia, reduced gluconeogenesis, and lactic acidemia, it is hypothesized that glucose-6-phosphatase may be a focal enzyme whose inactivation may be related to each of the disorders. Glucose-6-phosphatase is the terminal key enzyme in the gluconeogenesis pathway leading to increased blood glucose. Inhibition thereof may explain both the alternate reduction of pyruvate with concommittent increased formation of lactic acid, and the increase in the pentose phosphate pathway leading to hyperuricemia (as also observed in von Gierke's disease).

Coagulation protein function. IV. Effect of acetaldehyde upon factor X and factor Xa, the proteins at the gateway to the common coagulation pathway

Acetaldehyde (AcH) (447 mM) exerts an inhibition on Factor Xa, as followed by a clotting assay, but does not inhibit the hydrolysis of the synthetic fluorogenic substrate, N-tBOC-Ile-Glu-Gly-Arg-7-amido-4-methylcoumarin. These data suggest that AcH, although not reacting at the catalytic site of Factor Xa nor at the binding site for the synthetic substrate, does interact with the functional groups on the enzyme that bind to its natural substrate, prothrombin. As a consequence of such interaction, the charge and conformation of Factor Xa is altered, thereby limiting effective activation of prothrombin. Additionally, alkylation of factor Xa may also affect its capacity to associate with Factor Va for the activation of prothrombin. AcH also reacts with Factor X, prolonging clotting times when the zymogen is activated with Russell's viper venom (RVV). It also reduces the rate of hydrolysis of the fluorogenic substrate after activation of the alkylated zymogen by RVV. These data lead to the considerations that AcH-modified Factor X is no longer as effectively activated by RVV due to an alteration of its charge/conformation. Additional possibilities include a likely alkylation of the Factor Xa moiety of Factor X by AcH such that the activation product has an altered charge/conformation compared to native Factor Xa, including possible alkylation of its binding site(s) for prothrombin. The reduced rate of hydrolysis of the synthetic fluorogenic substrate for Factor Xa by the alkylated, activated Factor X lends further support to the generation of a modified Factor Xa by RVV, which may have a lower binding or catalytic rate for the fluorogenic substrate. These results support the suggestion that chronic consumption of alcohol may prolong the reported coagulation times as a result of reaction of alcohol's primary metabolite, AcH, with clotting factors, thereby reducing their physiological potential.

Coagulation protein function. III. Effect of acetaldehyde upon the activation of prothrombin

When prothrombin is mixed with acetaldehyde (AcH), the primary metabolite of ethanol, at room temperature for 30 min, dialyzed to remove excess AcH, and then activated with Echis carinatus venom (ECV), a prolonged clotting time is observed. Similarly treated prothrombin, however, readily hydrolyzes the synthetic substrate, benzoyl-DL-arginine-beta-naphthylamide (BANA). These results suggest that AcH does not react with the catalytic site of thrombin, which is protected in the prothrombin molecule. However, it does react with susceptible sites on the prothrombin surface which remain alkylated during extensive dialysis to remove excess AcH and subsequent activation of the molecule by ECV. These alkylated sites on the newly formed thrombin molecule may inhibit or prevent the effective/efficient binding of fibrinogen at its binding sites, causing prolonged clotting times. The binding sites for accommodating fibrinogen on the thrombin molecule are apparently quite different from those that bind BANA. These data further suggest that prolonged clotting times that are reported in chronic alcoholics may be due, in part, to ready interaction of acetaldehyde with circulating prothrombin. Fibrinogen, which has been exposed to AcH and subsequently dialyzed to remove excess AcH, also responds with a prolonged clotting time in the presence of added thrombin, signifying that sites on fibrinogen that are essential for its function/conformation are susceptible to AcH.